Author:
Martone Robert L.,Zhou Hua,Atchison Kevin,Comery Thomas,Xu Jane Z.,Huang Xinyi,Gong Xioahai,Jin Mei,Kreft Anthony,Harrison Boyd,Mayer Scott C.,Aschmies Suzan,Gonzales Cathleen,Zaleska Margaret M.,Riddell David R.,Wagner Erik,Lu Peimin,Sun Shaiu-Ching,Sonnenberg-Reines June,Oganesian Aram,Adkins Karissa,Leach Michael W.,Clarke David W.,Huryn Donna,Abou-Gharbia Magid,Magolda Ronald,Bard Jonathan,Frick Glen,Raje Sangeeta,Forlow S. Bradley,Balliet Carrie,Burczynski Michael E.,Reinhart Peter H.,Wan Hong I.,Pangalos Menelas N.,Jacobsen J. Steven
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmacology,Molecular Medicine
Reference47 articles.
1. Albright CF , Dockens R, Olson RE, Meredith J, Siemmon R, Lentz K, Wang J, Denton R, Pilcher G, Zaczek R, et al.. (2008) BMS-708163, a potent and selective γ-secretase inhibitor, decreases CSF Aβ at safe and tolerable doses in animals and humans (Abstract HT-01-05), in International Conference on Alzheimer's Disease; 2008 July 26–31; Chicago, IL. Alzheimer's Association, Chicago, IL.
2. Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor
3. Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site
4. Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]
5. The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression